We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




3D Digital Mammography Tomosynthesis System Receives US Approval

By HospiMedica International staff writers
Posted on 13 Dec 2010
A three-dimensional (3D) digital mammography system is a new application for breast cancer screening and diagnosis. More...
Unlike earlier generation mammography systems that produce two-dimensional images, breast tomosynthesis generates 3D images that are designed to reveal the inner architecture of the breast, free from the distortion typically caused by tissue shadowing or density.

Hologic, Inc. (Bedford, MA, USA), a developer, manufacturer, and supplier of diagnostics products, medical imaging systems and surgical products focused on the healthcare needs of women, announced that Hologic has received an approvable letter from the US Food and Drug Administration (FDA) for the Selenia Dimensions 3D digital mammography tomosynthesis system. Final approval of the company's premarket approval (PMA) application for the system remains subject to satisfactory review and inspection of our manufacturing facility, methods and controls. The company plans to work closely with the FDA to complete this final inspection.

"We are extremely pleased to have received the FDA's approvable letter, which represents an important step forward in the commercialization of our Selenia Dimensions tomosynthesis system,” said Rob Cascella, president and chief executive officer. "The Selenia Dimensions technology is designed to provide radiologists with enhanced screening and diagnostic capabilities through the incorporation of fast, high-quality 3D imaging in combination with 2D imaging. We believe this new technology will address many of the limitations present in stand-alone 2D imaging and improve upon both sensitivity and specificity. We look forward to working with the FDA to complete the remaining steps in the approval process.”

Hologic's Selenia Dimensions 3D system is available commercially in more than a dozen countries outside the United States, including countries in Europe, Latin America, and Asia. In North America, commercial systems are installed in Canada and Mexico. Hologic management held a press conference to discuss Selenia Dimensions technology on Monday, November 29, 2010, at the Radiological Society of North America (RSNA) annual meeting in Chicago, IL, USA.

Related Links:
Hologic




Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Enteral Feeding Pump
SENTINELplus
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Autoclave
Advance
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.